ACAD
ACADIAANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
DAYBUE is growing, NUPLAZID remains resilient, management reaffirmed FY2026 guidance, and the company has two dated 2H2026 program milestones supported by the May 2026 8-K exhibit.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Both remlifanserin and the Japan trofinetide program are binary catalysts; negative data would likely compress the multiple.
Momentum
74
Value
62
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $34.00 · Bear $15.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $32.65
Why
Momentum74 · Δ7d +2.3
Value62 · Δ7d -0.1
Sentiment48 · Δ7d -0.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
74
26% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
+27.3
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-0.9
Δ21d
-2.9
Why this grade
Composite grade A. Momentum 74.4 / Value 61.5 / Sentiment 48.4
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$4.39B
Beta
0.66
Shares Out
171.24M
P/E (TTM)
16.8
P/S (TTM)
4.22
P/FCF (TTM)
44.70
Rev YoY
+9.7%
EPS YoY
-81.4%
Gross Margin
+91.5%
Op Margin
+23.0%
Net Debt
-$767.5M
Current Ratio
3.59
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology